Drug reference

Ceftazidime with avibactam

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 580

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Complicated intra-abdominal infection ▶BY INTRAVENOUS INFUSION ▶Adult: 2/0.5 g every 8 hours for 5–14 days Complicated urinary tract infection, including pyelonephritis ▶BY INTRAVENOUS INFUSION ▶Adult: 2/0.5 g every 8 hours for 5–10 days Hospital-acquired pneumonia, including ventilator- associated pneumonia ▶BY INTRAVENOUS INFUSION ▶Adult: 2/0.5 g every 8 hours for 7–14 days Infections due to Gram-negative bacteria with limited treatment options ▶BY INTRAVENOUS INFUSION ▶Adult: 2/0.5 g every 8 hours, duration of treatment guided by infection severity, pathogen, and response DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y g ceftazidime/avibactam

PDF page 580

Safety

Interactions

→Appendix 1: cephalosporins

PDF page 580

Side Effects

▶Common or very common Increased risk of infection. thrombocytosis ▶Uncommon Acute kidney injury. antibiotic associated colitis. lymphocytosis. paraesthesia. taste altered ▶Frequency not known Coma. encephalopathy. jaundice. myoclonus. neurological effects. seizures. tremor

PDF page 580

Pregnancy

Manufacturer advises avoid unless potential beneﬁt outweighs risk—toxicity in animal studies.

PDF page 580

Breast Feeding

Manufacturer advises avoid—presence of avibactam in milk unknown.

PDF page 580

Dose and formulations

Directions For Administration

Manufacturer advises for intravenous infusion (Zavicefta ®) give in Glucose 5%, or Sodium Chloride 0.9%, or Sodium Chloride 0.45% with Glucose 2.5% combination or Lactated Ringer’s solution. Reconstitute each 2 g/0.5 g vial with 10 mL water for injections; dilute requisite dose in an appropriate infusion bag and give over 120 minutes.

PDF page 580

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ELECTROLYTES: May contain Sodium ▶Zavicefta (Pfizer Ltd) A Avibactam (as Avibactam sodium) 500 mg, Ceftazidime (as Ceftazidime pentahydrate) 2 gram Zavicefta 2g/0.5g powder for concentrate for solution for infusion vials | 10 vial P £857.00 (Hospital only) eiiii F 550

PDF page 580

Clinical care

Patient And Carer Advice

Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—risk of dizziness.

PDF page 580

Dose text by age group

Adult

2/0.5 g every 8 hours for 5–14 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Adult

2/0.5 g every 8 hours for 5–10 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Adult

2/0.5 g every 8 hours for 7–14 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Adult

2/0.5 g every 8 hours, duration of treatment

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Ceftazidime with avibactam

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 580

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 580

Safety

Interactions

→Appendix 1: cephalosporins

PDF page 580

Side Effects

PDF page 580

Pregnancy

Manufacturer advises avoid unless potential beneﬁt outweighs risk—toxicity in animal studies.

PDF page 580

Breast Feeding

Manufacturer advises avoid—presence of avibactam in milk unknown.

PDF page 580

Dose and formulations

Directions For Administration

PDF page 580

Medicinal Forms

PDF page 580

Clinical care

Patient And Carer Advice

Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—risk of dizziness.

PDF page 580

Dose text by age group

Adult

2/0.5 g every 8 hours for 5–14 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Adult

2/0.5 g every 8 hours for 5–10 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Adult

2/0.5 g every 8 hours for 7–14 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Adult

2/0.5 g every 8 hours, duration of treatment

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.